📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
Why DMPK is the glue of R&D
DMPK influence starts at the very beginning and transcends into the clinic and beyond, arguably…
News
Leading UK Drug Discovery CROs Unite as Sygnature Discovery
Over the past few years Sygnature Discovery has acquired two of the UK’s…
Blog
The Opportunity in Treating Obesity
Obesity has been increasing rapidly over recent decades, and is often described today as a…
Journal Papers
Impact of Mitochondrial Targeting Antibiotics on Mitochondrial Function and Proliferation of Cancer Cells
Edward J Cochrane, James Hulit, Franz P Lagasse, Tanguy Lechertier, Brett Stevenson, Corina Tudor, Diana…
News
Legendary Werewolf: A Freak Chemistry Accident at Sygnature!
During a routine tour of the chemistry labs here at BioCity, Nottingham, Sygnature’s Senior VP…
Blog
5 key things to look for in a drug discovery CRO partnership
In today’s world of collaborative drug discovery, where in-house science is regularly combined with CRO…
Blog
Delivering better cancer therapies
As far back as 2500 BC, cases of the disease we now call cancer were…
News
Sygnature Discovery expands US presence with Bay Area office
Sygnature Discovery has established a new office presence in South San Francisco’s biotech hub at…
News
Sygnature Discovery renforce sa présence aux États-Unis avec un bureau dans la région de la baie de San Francisco.
Sygnature Discovery a ouvert un nouveau bureau à Oyster Point, le pôle biotechnologique de South…
News
Sygnature Discovery renforce sa présence aux États-Unis avec un bureau dans la région de la baie de San Francisco.
Sygnature Discovery a ouvert un nouveau bureau à Oyster Point, le pôle biotechnologique de South…
Blog
2D vs 3D fragments: why 3D is not the always the winner in fragment-based screening
Fragment-based screening has become commonplace in drug discovery, and for good reason. But while…
News
Sygnature appoints Dr David Lustig to spearhead US expansion
Sygnature Discovery has appointed Dr David Lustig to the role of Vice President Business Development…
Blog
Navigating the Physicochemical Maze
The way a human body interacts with and processes a drug molecule is dependent upon…
News
Sygnature gains ISO:27001 certification for information security
Sygnature’s dedication to cybersecurity has been officially acknowledged through the attainment of ISO:27001:2013 certification—an esteemed…
Blog
PROTACs: a hard road, but one worth taking?
There has been a lot of interest in the potential of PROTACs – protein-targeting chimeras…
Journal Papers
Molecularly profiled trials: toward a framework of actions for the “nil actionables”
Molecularly profiled trials for 'nil actionables' in cancer treatment. Dr. Allan Jordan suggests a framework for better therapeutic opportunities through data engagement
Blog
New paper: The next genetic revolution in cancer treatment?
While there have been huge advances in cancer treatment in recent years, far too many…
Blog
All FTEs are not created equal
As outsourcing becomes more and more prevalent in drug discovery programmes, the standardised FTE…
News
Sygnature Discovery’s Early CMC Development Expansion: Unveiling New Opportunities
Sygnature has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at…
News
Five Arrows invests in Sygnature Discovery
Sygnature Discovery has received a significant investment from Five Arrows Principal Investments,…
Blog
Covid-19 – impacts beyond the pandemic
The impact of the Covid-19 pandemic on public health is hard to understate.  Globally,…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch